Publications

5803 Results

Effect of adding ibritumomab tiuxetan (Zevalin) radioimmunotherapy consolidation to three cycles of CHOP plus involved-field radiotherapy for high risk limited stage aggressive diffuse B-cell lymphoma (Southwest Oncology Group Study 0313)

Authors
TP Miller;JM Unger;CM Spier;B Stea;OW Press;M LeBlanc;RI Fisher
Journal / Conference
Blood 112(11):1231, abst. #3598
Year
2008
Research Committee(s)
Lymphoma
Study Number(s)
S0313

Results of the p53 targeted therapy trial for patients with organ confined node negative bladder cancer treated with radical cystectomy

Authors
SP Lerner;JP Stein;E Tuazon;DG Skinner;D Raghavan;D Esrig;WM Stadler;S Groshen;G Steinberg;R Cote;C Hall
Journal / Conference
Society of Urologic Oncology 2008 Annual Meeting (oral presentation)
Year
2008
Research Committee(s)
Genitourinary
Study Number(s)
4B951

Updated results of SWOG 8794: adjuvant radiation for high risk prostate cancer

Authors
GP Swanson;IM Thompson;CM Tangen;JC Paradelo;ED Canby-Hagino;ED Crawford;MS Lucia;JD Forman;JL Chin;EM Messing
Journal / Conference
Radiotherapy and Oncology 88(S2):S148(449)
Year
2008
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8794

Prognostic significance of pathologic SV involvement and the effect of adjuvant radiation therapy on outcome

Authors
GP Swanson;IM Thompson;B Goldman;CM Tangen;JL Chin;EM Messing;ED Canby-Hagino;JD Forman;ED Crawford
Journal / Conference
Radiotherapy and Oncology 88(S2):S337(1057)
Year
2008
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8794

Update of SWOG 8794: adjuvant radiotherapy of pT3 prostate cancer improves metastasis free survival

Authors
GP Swanson;IM Thompson;CM Tangen;JC Paradelo;ED Canby-Hagino;ED Crawford;GJ Miller;MS Lucia;JD Forman;JL Chin
Journal / Conference
International Journal of Radiation Oncology Biology Physics 72(1)suppl. 1:S31
Year
2008
Research Committee(s)
Genitourinary
Study Number(s)
SWOG-8794

Molecular signatures implicate innate immune cells, fibrosis, and angiogenesis in survival following R-CHOP treatment of diffuse large B cell lymphoma

Authors
G Lenz;G Wright;SS Dave;W Xiao;H Zhao;W Xu;B Tan;N Goldschmidt;J Iqbal;J Vose;M Bast;K Fu;DD Weisenburger;TC Greiner;JO Armitage;A Kyle;L May;RD Gascoyne;JM Connors;G Troen;H Holte;H Holte;S Kvaloy;D Dierickx;G Verhoef;J Delabie;EB Smeland;P Jares;A Martinez;A Lopez-Guillermo;E Montserrat;E Campo;RM Braziel;TP Miller;LM Rimsza;JR Cook;B Pohlman;JW Sweetenham;RR Tubbs;RI Fisher;E Hartmann;A Rosenwald;G Ott;HK Muller-Hermelink;D Wrench;TA Lister;ES Jaffe;WH Wilson;LM Staudt
Journal / Conference
Blood 112(11)181 abst. 475
Year
2008
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

Genome-wide expression profiling predicts treatment outcome in classical hodgkin lymphoma

Authors
C Steidl;T Lee;SP Shah;G Han;T Nayar;A Delaney;WC Chan;A Rosenwald;LM Rimsza;E Campo;ES Jaffe;LM Staudt;G Lenz;JM Connors;RD Gascoyne
Journal / Conference
Blood 112(11):196 Abst. 520
Year
2008
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

Genetic abnormalities involved in the development and progression of follicular lymphoma

Authors
KE Deffenbacher;GL Wright;J Iqbal;H Geng;D O'Shea;TA Lister;JF Fitzgibbon;K Fu;A Liu;D Weisenburger;TC Greiner;RD Gascoyne;A Rosenwald;E Campo;LM Rimsza;J Delabie;ES Jaffe;LM Staudt;WC Chan
Journal / Conference
Blood 112(11):714, Abst. 2049
Year
2008
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclosphosphamide in women with operable, node positive breast cancer

Authors
PA Ganz;SR Land;CE Geyer;JP Costantino;ER Pajon;L Fehrenbacher;JN Atkins;JA Pollikoff;VE Vogel;JK Erban;RB Livingston;EA Perez;EP Mamounas;N Wolmark;SM Swain
Journal / Conference
San Antonio Breast Cancer Symposium, Abstract #76
Year
2008
Research Committee(s)
Breast

Phase II evaluation of neoadjuvant chemotherapy and interval debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube, or primary peritoneal cancer: A Southwest Oncology Group study

Authors
A Tiersten;P Liu;H Smith;SP Wilczynski;WR Robinson;M Markman;DS Alberts
Journal / Conference
Gynecologic Oncology 108(3) suppl. 1:S3
Year
2008
Research Committee(s)
Gynecologic
Study Number(s)
S0009